|Enzymatica AB -- Sweden Stock|| |
SEK 3.61 0.19 5.00%
Executive VP of Marketing and Operations
Mr. Ulf Blom has served as Executive Vice President Marketing and Operations at Enzymatica AB since 2011. He was Member of the Company Board of Directors from 2007 until May 6, 2013. He is CoFounder of the Company. He holds a MS degree in Economics and Business Administration and has over 15 years of experience in various positions within marketing and sales in the pharmaceutical industry, both nationally and internationally, including such companies as Novo Nordisk, Astra Zeneca and ALK. He also has experience in all strategic phases of drug commercialization on a global scale. He is Board Member and CEO of Medzyme Invest Oresund AB and Board Member of Enzymatica Care AB and Idogen AB.
Age: 51 EVP Since 2013
46 4 62 86 31 00 http://www.enzymatica.se
The company has return on total asset (ROA)
of (12.74) %
which means that it has lost $12.74 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE)
of (24.88) %
meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 8.02 M in total debt with debt to equity ratio (D/E) of 7.2 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Enzymatica AB has Current Ratio of 1.81 which is within standard range for the sector.
Enzymatica AB , a life science company, develops and sells medical device products against infectious-related diseases. The company was founded in 2007 and is headquartered in Lund, Sweden. Enzymatica AB operates under Pharmaceuticals And Biosciences classification in Sweden and traded on Stockholm Stock Exchange exchange. It employs 21 people.Enzymatica AB (ENZY) is traded on Stockholm Stock Exchange in Sweden. It is located in Ideon Science Park and employs 21 people.